RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection
- Matthew Nodelman; A. Miles Scott
PMID: 38905561
Access Resources
About
This article provides an overview of the RSVpreF vaccine and nirsevimab-alip for the prevention of severe lower respiratory tract infections from respiratory syncytial virus (RSV). RSVpreF is a vaccine for respiratory syncytial virus (RSV), approved for individuals aged 60 and above and for pregnant women to protect infants from severe lower respiratory tract infections. Nirsevimab-alip is a monoclonal antibody for infants in their first RSV season and children up to 24 months old at risk of severe RSV disease in their second season.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.